clemastine and Cancer of Lung

clemastine has been researched along with Cancer of Lung in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Behr, J; Herzinger, T; Przybilla, B	1
den Bakker, MA; Gelderblom, H; Kloover, JS; van Meerbeeck, JP	1
Diergarten, K; Goes-Schmieder, R; Kober, B; Kolotas, C; Martin, T; Mitrou, PS; Schneider, LV; Vogt, HG; Zamboglou, N	1

Trials

1 trial(s) available for clemastine and Cancer of Lung

Article	Year
Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study. Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 16 Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clemastine; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication; Radiation-Sensitizing Agents; Radiotherapy Dosage; Ranitidine; Remission Induction; Treatment Outcome	1996

Article

Year

Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.

Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 16

Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clemastine; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Premedication; Radiation-Sensitizing Agents; Radiotherapy Dosage; Ranitidine; Remission Induction; Treatment Outcome

1996

Other Studies

2 other study(ies) available for clemastine and Cancer of Lung

Article	Year
[Tolerance induction in anaphylaxis to carboplatin]. Deutsche medizinische Wochenschrift (1946), 2003, Jul-25, Volume: 128, Issue:30 Topics: Abdominal Neoplasms; Aged; Anaphylaxis; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cimetidine; Clemastine; Combined Modality Therapy; Desensitization, Immunologic; Dexamethasone; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Indoles; Infusions, Intravenous; Lung Neoplasms; Ovarian Neoplasms; Premedication; Tropisetron	2003
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2 Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clemastine; Dexamethasone; Drug Hypersensitivity; Fatal Outcome; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Ranitidine; Risk Factors	2004

Article

Year

[Tolerance induction in anaphylaxis to carboplatin].

Deutsche medizinische Wochenschrift (1946), 2003, Jul-25, Volume: 128, Issue:30

Topics: Abdominal Neoplasms; Aged; Anaphylaxis; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cimetidine; Clemastine; Combined Modality Therapy; Desensitization, Immunologic; Dexamethasone; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Indoles; Infusions, Intravenous; Lung Neoplasms; Ovarian Neoplasms; Premedication; Tropisetron

2003

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.

British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2

Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clemastine; Dexamethasone; Drug Hypersensitivity; Fatal Outcome; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Ranitidine; Risk Factors

2004